Investment
Features
FeesSafety
Academy
More
Pluang+
|
Home/Explore/US Market Price/Stocks/INCY
icon
Us company
Asset icon - trade crypto, stocks, and gold on Pluang

Incyte Corporation (INCY) Stock Price Today

TechnicalsFundamentalsFinancialsNewsCorp ActionAboutCompare
24H
1W
1M
3M
YTD
1Y
5Y

Aura AI Summary

Incyte Corporation (INCY) trades at $125.31, down 1.81% today but maintains a strong 23% year-to-date gain. The stock shows bullish technical signals with moving averages supporting upward momentum, while fundamentals reveal robust revenue growth from $5.14B in 2025 to projected $5.8B in 2026 and exceptional profitability with 92.62% gross margins. Recent earnings beats in Q1 and Q2 2026 offset a Q4 2025 miss, with analysts maintaining a Buy consensus.
Investment outlook remains positive given strong product demand and pipeline progress, though valuation at 15.96 P/E requires monitoring. Key risks include Q3 2026's expected EPS loss and competitive pressures. With 52% analyst Buy ratings and $130.07 consensus target offering 4% upside, the stock presents growth potential balanced by near-term earnings volatility.
Read full analysis

Key Stats

  • Market Cap
    $25.40B
  • Volume
    3,700,438
  • Sector
    Health
  • 52W High
    $129.93
  • 52W Low
    $81.66
  • Typical Hold Time
    32 Days
  • Enterprise Value
    $20.90B
  • Div Yield
    -
  • Trading Activity
    -
$126.49
52W Low: $81.66
25 Sep 2025
52W High: $129.93
28 Jul 2026

Track Incyte Corporation (INCY) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, Incyte Corporation has traded between a low of $81.66 and a high of $129.93, highlighting its annual price range. Buy and sell Incyte Corporation shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.

About Incyte Corporation

Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.

Most Recent News

Content is generated by Aura AI

A2Gold reports highest-grade gold assay at Eastside, revealing new targets for higher-grade mineralization.

A2Gold Corp announced the highest-grade gold assay to date at its Eastside Gold-Silver Project in Nevada, with a drill hole intersecting 141.10 g/t gold over 0.9 meters. This discovery supports a new geological model focusing on structurally controll...

Market News
4 hours ago
PRNewsWire
Bullish
news icon
A2Gold reports highest-grade gold assay at Eastside, revealing new targets for higher-grade mineralization.

Gold Strike Resources joins Yukon Mining Alliance to boost visibility of its gold projects in Yukon.

Gold Strike Resources Corp. has joined the Yukon Mining Alliance, a group promoting Yukon as a top mining jurisdiction. This membership will help Gold Strike showcase its Florin Gold Project and other assets in the promising Tombstone Gold Belt, whic...

Market News
4 hours ago
Newsfile Corp
Bullish
news icon
Gold Strike Resources joins Yukon Mining Alliance to boost visibility of its gold projects in Yukon.

Great Pacific Gold confirms large gold-bearing system at Kasie Ridge in Papua New Guinea with promising drill results.

Great Pacific Gold Corp. reported successful results from its first drill program at the Kasie Ridge target within its Wild Dog Project in Papua New Guinea. Two drill holes confirmed a large, high-temperature magmatic-hydrothermal system with gold-be...

Market News
4 hours ago
Newsfile Corp
Bullish
news icon
Great Pacific Gold confirms large gold-bearing system at Kasie Ridge in Papua New Guinea with promising drill results.
Catch up fast with Aura AI
Get an AI-generated news summary for this asset in seconds.

People also bought

Frequently Asked Questions

US stocks trading hours: Monday - Friday (Except for US public holidays) Time: 21.30 - 04.00 WIB 20.30 - 03.00 WIB (Daylight Savings Time*) *The next Daylight Savings is scheduled to begin on March 13, 2022 and ends on November 6, 2022. You can place limit orders outside of the trading hours, but it can only be executed during trading hours. For illustration, a stock is currently trading at $10 per share, but you only want to pay $7 per share at most. Let’s say you set your limit price to $7 at 18.00. Your order will be executed when the market is open at 21.30 if the stock drops from $10 to $7 or lower. Similarly, if the stock price doesn’t drop to $7, your order won’t be executed.
Yes, you are eligible to receive dividend payment if and when the company pays them on one condition: minimum net dividend paid is at least $0.01. Net dividend is gross dividend subtracted by 15% withholding tax.
Yes, it is. US Stocks risk is managed by PT PG Berjangka which is licensed by Badan Pengawas Perdagangan Berjangka Komoditi (BAPPEBTI), and your investment is guaranteed by Jakarta Futures Exchange (JFX) and Indonesian Clearing House (KBI).
Pluang charges a fixed transaction fee of 0.30% for regular users and 0.20% for Pluang Plus members, including VAT to cover the exchange fees and operational costs.
US Stocks, ETFs, and Options are facilitated by PT PG Berjangka in its capacity as a Licensed Derivatives Broker supervised by the Financial Services Authority of Indonesia (OJK) for financial derivative products with underlying securities. All transactions are recorded on the Jakarta Futures Exchange (JFX) and the Indonesian Futures Clearing House (KBI). In addition, PT PG Berjangka is also a Licensed Futures Broker supervised by the Commodity Futures Trading Regulatory Agency (Bappebti). Read our product’s Terms and Conditions

All investments involve risks and the possibility of a loss in investment value. Past performance is not indicative of future results. Historical performance, expected returns, and probability projections are provided for informational and illustrative purposes only.

Key Stats

  • Market Cap
    $25.40B
  • Volume
    3,700,438
  • Sector
    Health
  • 52W High
    $129.93
  • 52W Low
    $81.66
  • Typical Hold Time
    32 Days
  • Enterprise Value
    $20.90B
  • Div Yield
    -
  • Trading Activity
    -
$126.49
52W Low: $81.66
25 Sep 2025
52W High: $129.93
28 Jul 2026

Track Incyte Corporation (INCY) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, Incyte Corporation has traded between a low of $81.66 and a high of $129.93, highlighting its annual price range. Buy and sell Incyte Corporation shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.

Let’s invest in this asset by signing up or download!